Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. - Wikidata - awgldk - TriplyDB

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

http://www.wikidata.org/entity/Q37086937

about

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials The role of lipoxygenases in pathophysiology; new insights and future perspectives Frizzled homolog proteins, microRNAs and Wnt signaling in cancer Solution structure and dynamic analysis of chicken MBD2 methyl binding domain bound to a target-methylated DNA sequence Recurrent DNMT3A mutations in patients with myelodysplastic syndromes Therapy-related myeloid neoplasms: pathobiology and clinical characteristics Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms Demethylating Agents in the Treatment of Cancer DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia.Heparan sulfate 3-O-sulfation: a rare modification in search of a function.Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.Epigenetic changes in the myelodysplastic syndrome.Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.Oxidative stress and DNA methylation in prostate cancer.Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles.TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes.Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia Rare occurrence of DNMT3A mutations in myelodysplastic syndromes.TET family proteins and their role in stem cell differentiation and transformation.Cigarette Smoking and the Risk of Adult Myeloid Disease: A Meta-Analysis.Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia

P2860

Q24306181-433D521E-8DA9-4704-8FDA-8F91FEED5B28 Q24632949-6D4DD318-4D00-458B-8CDA-D1933D75F282 Q26745731-19C425CD-BCD8-4A30-BF5A-927BE3B27FD1 Q26795652-C9BC8D5B-848C-414F-B3D5-010B459E4EA4 Q27010132-25137951-AB3A-4774-8653-B320EC797443 Q27667623-12033AB1-CC46-4422-B464-6A83B5DC8E89 Q27851629-FCB2890B-76BD-49EB-AADC-51593566743D Q28386366-BB15B748-1E76-4386-A34E-449BE80BB91C Q28535153-0D420305-3B87-4472-A5B5-50FE0191DF8B Q30235355-BF9A5F4B-3D51-44DB-9CEB-5895C1790D02 Q33502760-8BA79A61-9EA8-4253-B921-B747A635C4DD Q33678040-5F1FD2A3-9E96-456F-A329-34D42D2E1919 Q33680945-A43AAB6E-CF1B-4052-B457-133613A8FCC3 Q33690545-81B12E62-1648-449F-ADDB-ADB8801EFDCE Q33741025-D24C8C05-A42B-4ABA-90AB-59BC66D8F52F Q33767309-C7E616EE-2C47-42DB-9D08-AD1812AA55CD Q33772607-F2017A2B-2928-43C6-B423-31DCF6DBBA1E Q33813750-4B35BFF5-D29A-4B02-9C02-212382DF7167 Q33961765-2F4A8BA4-FD28-4B2A-B17A-002A62F31CDB Q34021985-24467F1F-8C2F-46BE-BE50-5E2F706701F5 Q34071483-F6581482-CE97-4E1E-AFAF-62BBDF7BBADE Q34157339-5E7D81DF-892C-46EB-BF1E-280E264AC833 Q34221688-451A61DA-9B82-4213-905C-30BD075FC833 Q34273735-DFB6CFBB-6A81-41C2-BB2C-7D5097001325 Q34342944-715DD5E0-3213-45A4-9E79-78B365F4D777 Q34350209-A196CF90-99CA-45A7-BBE3-C500976C1FE1 Q34359695-9EF18840-8F30-48E9-87A0-C82803D1F3D5 Q34502726-7E273F5E-D511-448D-A011-80648F749AE9 Q34643306-019032E2-003F-43D2-A6DC-359E3253E37E Q34651312-DAB60E16-71E4-4D0F-8D9C-370E55697479 Q34955338-60271987-C6BE-4DA5-80F8-20FBB0C3EF68 Q35107545-1BEF0D83-AB02-4D17-87F8-D9B39E296038 Q35108501-CC68EEB6-6DF6-41F8-9B76-B67D54621703 Q35124582-0D9F7D72-F9A7-4A15-B46F-014FCF196FBD Q35254822-8AAC4D35-B0C2-499C-A75A-6A5E7ACE2BCA Q35585976-882CAF3B-59CC-4DA2-88B0-80DFA97DB088 Q35596955-B362A5F3-521E-4461-808A-B2E4A5A04EA0 Q35630033-0EF2A54A-00A8-4860-9596-3C097C5D4E44 Q35764589-5D78E107-B8BD-41FD-9C36-2B3017833D37 Q35816855-DE5AE686-F57A-4699-84BA-B8289F0E7720

P2860

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

http://www.wikidata.org/entity/Q37086937

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

@en

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

@nl

type

label

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

@en

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

@nl

prefLabel

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

@en

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

@nl

P1433

Q37086937-5C2D38A5-2C08-4F36-84D1-9BF63CDAF950

P1476

Q37086937-D2A4C6FB-4A88-4884-A0C4-DF6261F6C2E8

P2093

Q37086937-083AA69A-4A21-4071-AD2A-B833C40416CC

Q37086937-2656BE08-BC30-48B6-A5F7-814821BE66A2

Q37086937-2BC6B34B-B66E-42A4-AACD-B844682F246E

Q37086937-79844E9B-3264-4D96-828B-2340A471B543

Q37086937-86034DDF-304D-4AF0-905D-575496DE754F

Q37086937-C3A3D869-E56F-499E-A2C8-DFF55F04624C

Q37086937-CCFF3335-D500-4EF8-8F38-3BF3D30813BF

Q37086937-E52F031A-C3F0-44DB-8E02-A0DA7D07C621

Q37086937-FD8A146A-8812-4F73-B5AF-3D07FD718E02

P2860

Q37086937-0E209E19-8E70-4105-B964-005EA725A540

Q37086937-12B26D5F-D3E6-4CAB-9CBD-341D1E0F6577

Q37086937-130ADD64-3141-4376-9D07-18154BD6489D

Q37086937-24E2403A-04FA-4D38-95E7-00F9049FEBB3

Q37086937-2C779A79-05E8-4344-BD74-FE15F159B62E

Q37086937-2F2B0935-0DF0-4CC3-90AE-ACFB645D615A

Q37086937-3477FE41-B41C-41F3-9CAF-3F4104F788EC

Q37086937-4BFDBB53-414C-44C2-A570-5B04A791E127

Q37086937-5426B6C6-B419-416A-8A5C-0E81331E5E30

Q37086937-58431D17-33CC-4335-87F6-B1B20D10A60A

P304

Q37086937-3735BBFB-9B1E-454E-8CB7-BCCA20B0B189

P31

Q37086937-0B341B9F-2914-4C2C-B4F9-D8FCA107EF1F

P356

Q37086937-5451FC0E-A53D-465B-89F2-0384FE3E94DA

P407

Q37086937-7742FF27-2439-43D4-AA0F-8CC6A69288B4

P433

Q37086937-1594B273-1584-4CE7-B06E-CDA831A51478

P478

Q37086937-B02E83AD-DFA7-49B6-BFF0-56E2CA062BCB

P577

Q37086937-6E61805A-BF77-4194-B6BE-D47F86EC4184

P5875

Q37086937-A7AE0198-01A8-41E7-B580-C43F6355E7C9

P698

Q37086937-3FD2920A-4BD3-487B-85CD-7C587EEAFAB7

P921

Q37086937-C0D83B9B-4466-4585-9CB6-9978A29D96EA

P932

Q37086937-D9B58C2A-2DAA-4FFB-88AD-3D4A41763A6C

P356

BLOOD-2008-06-163246

P1433

P1476

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

@en

P2093

Andrew Dunbar

http://www.w3.org/2001/XMLSchema#string

Christine O'Keefe

http://www.w3.org/2001/XMLSchema#string

Jaroslaw P Maciejewski

http://www.w3.org/2001/XMLSchema#string

Lukasz P Gondek

http://www.w3.org/2001/XMLSchema#string

Manjot Rataul

http://www.w3.org/2001/XMLSchema#string

Mikkael Sekeres

http://www.w3.org/2001/XMLSchema#string

Sanjay Mohan

http://www.w3.org/2001/XMLSchema#string

Ying Jiang

http://www.w3.org/2001/XMLSchema#string

Yogen Saunthararajah

http://www.w3.org/2001/XMLSchema#string

P2860

Mutation and cancer: statistical study of retinoblastoma

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays

The International HapMap Project

The consensus coding sequences of human breast and colorectal cancers

The genomic landscapes of human breast and colorectal cancers

Frizzled-9 is activated by Wnt-2 and functions in Wnt/beta -catenin signaling

Genetic instabilities in human cancers

Hypermethylation of gene promoters in hematological neoplasia

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies

P304

1315-1325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-06-163246

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23297223

http://www.w3.org/2001/XMLSchema#string

P698

18832655

http://www.w3.org/2001/XMLSchema#string

P921

DNA methylation

P932

2637194

http://www.w3.org/2001/XMLSchema#string